Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eliem Therapeutics (ELYM)
NASDAQ:ELYM
Holding ELYM?
Track your performance easily
ELYM Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.35 - $11.55
Previous Close$7.98
Volume262.98K
Average Volume (3M)262.70K
Market Cap
$567.33M
Enterprise Value$312.10M
Total Cash (Recent Filing)$223.14M
Total Debt (Recent Filing)$100.00K
Price to Earnings (P/E)―
Beta-0.43
Next Earnings
Nov 04, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding67,060,163
10 Day Avg. Volume294,611
30 Day Avg. Volume262,700
Standard Deviation0.32
R-Squared0.00308
Alpha0.00366
Financial Highlights & Ratios
Price to Book (P/B)2.41
Price to Sales (P/S)16175.72
Price to Cash Flow (P/CF)-200.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.46K
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.54
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Eliem Therapeutics News
PremiumCompany Announcements
Eliem Therapeutics: Executive Changes Amid Strategic Shift
PremiumCompany Announcements
Eliem Therapeutics Names Brett Kaplan as New COO
Ownership Overview
16.02% Insiders
0.61% Mutual Funds
68.48% Other Institutional Investors
14.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ELYM FAQ
What was Eliem Therapeutics’s price range in the past 12 months?
Eliem Therapeutics lowest stock price was $2.35 and its highest was $11.55 in the past 12 months.
What is Eliem Therapeutics’s market cap?
Currently, no data Available
When is Eliem Therapeutics’s upcoming earnings report date?
Eliem Therapeutics’s upcoming earnings report date is Nov 04, 2024 which is in 45 days.
How were Eliem Therapeutics’s earnings last quarter?
Eliem Therapeutics released its earnings results on Aug 14, 2024. The company reported -$1.81 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.81.
Is Eliem Therapeutics overvalued?
According to Wall Street analysts Eliem Therapeutics’s price is currently Overvalued.
Does Eliem Therapeutics pay dividends?
Eliem Therapeutics does not currently pay dividends.
What is Eliem Therapeutics’s EPS estimate?
Eliem Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eliem Therapeutics have?
Eliem Therapeutics has 67,060,165 shares outstanding.
What happened to Eliem Therapeutics’s price movement after its last earnings report?
Eliem Therapeutics reported an EPS of -$1.81 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.376%.
Which hedge fund is a major shareholder of Eliem Therapeutics?
Among the largest hedge funds holding Eliem Therapeutics’s share is RA Capital Management. It holds Eliem Therapeutics’s shares valued at 223M.
---
Eliem Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ELYM Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 18.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $46.5M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
205.74%
12-Months-Change
Fundamentals
Return on Equity
-38.35%
Trailing 12-Months
Asset Growth
94.38%
Trailing 12-Months
Company Description
Eliem Therapeutics
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.
---
ELYM Stock 12 Month Forecast
Average Price Target
―Technical Analysis
ATAI Life Sciences
―
Verrica Pharmaceuticals
―
Bioxcel Therapeutics
―
SELLAS Life Sciences Group
―
---